Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative Letrozole Duration and Surrogate Markers in Breast Cancer
NCT00535418Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2000
- Primary completion
- Jul 2002
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of letrozole in breast cancer, sponsored by Novartis. Primary endpoint: Optimal Duration of Pre-operative Treatment. Started Jun 2000; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00535418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00535418.